Bellevue Group’s Voyager Therapeutics VYGR Stock Holding History

Bellevue Group’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-31,800	Closed	-$150K	–	224
2021 Q1	$150K	Sell	31,800 -2,680,283	-99%	-$18.3M	﹤0.01%	216
2020 Q4	$19.4M	Hold	2,712,083	–	–	0.22%	102
2020 Q3	$28.9M	Hold	2,712,083	–	–	0.4%	69
2020 Q2	$34.2M	Sell	2,712,083 -12,000	-0.4%	-$140K	0.48%	53
2020 Q1	$24.9M	Buy	2,724,083 +19,800	+0.7%	+$227K	0.48%	54
2019 Q4	$37.7M	Sell	2,704,283 -400	-0%	-$5.81K	0.6%	44
2019 Q3	$46.5M	Buy	2,704,683 +24,400	+0.9%	+$512K	0.87%	35
2019 Q2	$73M	Buy	+2,680,283	New	+$61.3M	1.25%	24
2019 Q1	–	Sell	-27,900	Closed	-$262K	–	149
2018 Q4	$262K	Sell	27,900 -15,522	-36%	-$199K	0.02%	136
2018 Q3	$822K	Buy	43,422 +26,500	+157%	+$508K	0.05%	129
2018 Q2	$331K	Buy	+16,922	New	+$334K	0.03%	137

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bellevue Group's VYGR Position: Q2 2021 in Review

Bellevue Group sold out of Voyager Therapeutics (VYGR) in Q2 2021, closing a stake of 31,800 shares — an estimated $150K sold.

Bellevue Group first reported a position in VYGR in Q2 2018 and held it in 11 quarters. The position peaked at $73M in Q2 2019. 78 funds tracked by Wall St. Rank hold VYGR as of Q2 2021.

Bellevue Group reported no remaining Voyager Therapeutics position as of Q2 2021 after selling out during the quarter.
Bellevue Group sold 31,800 Voyager Therapeutics shares in Q2 2021, an estimated $150K.
Bellevue Group first reported a position in Voyager Therapeutics in Q2 2018 and held it in 11 quarters.
Bellevue Group's Voyager Therapeutics position peaked at $73M in Q2 2019.
78 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2021.

Based on Bellevue Group's 13F filing for Q2 2021, filed 12 Aug 2021.